CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

Explore clinical trials studying CCCA Assessed by Ki67 Drop Below <2.7% From Baseline. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study

Refine in advanced search Browse all conditions

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline trial results

Recruiting

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

NCT06607757

Conditions: CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
Locations: Haematologie-Onkologie im Zentrum MVZ GmbH Augsburg, Germany

Charité Berlin, Germany

Onkologische Schwerpunktpraxis - Studiengesellschaft Onkologie Bielefeld GbR Bielefeld, Germany

Hämato-Onkologie im Medicum - Onkologie und Hämatologie Bremen, Germany

View all 25 locations

View Trial Details